Benefits
Niacin-Form Marketed as Flush-Free
IHN is positioned as a niacin-providing supplement that avoids the warm flushing reaction associated with immediate-release nicotinic acid. Users sensitive to flushing may prefer this form, though its biological activity differs substantially from that of free niacin.
Traditional Use in Vascular Comfort
European clinicians have historically used IHN under the name Hexopal for conditions involving peripheral circulation, with small early trials suggesting subjective improvements in cold-hand symptoms in Raynaud's phenomenon.
Source of Inositol and Niacin Building Blocks
Although release of free nicotinic acid is limited, IHN does provide the molecular components of inositol and niacin to the body, contributing in small amounts to overall intake of these nutrients.
Reported Mild Tolerability
Trial data indicate IHN is generally well tolerated at typical supplement doses, with side effects comparable to placebo in published studies — though this favorable tolerability profile also reflects its limited pharmacologic activity.
Mechanism of action
Slow Ester Hydrolysis (Proposed)
IHN was designed on the assumption that intestinal and tissue esterases would slowly hydrolyze the ester bonds to release nicotinic acid gradually. In practice, human pharmacokinetic data show this release is minimal at typical supplement doses.
Minimal Nicotinic Acid Bioavailability
Clinical pharmacokinetic studies in humans have demonstrated that oral IHN produces very low plasma concentrations of free nicotinic acid compared with immediate- or extended-release niacin, explaining the lack of robust lipid effects.
Niacinamide Conversion
A portion of any niacin released from IHN is rapidly converted to niacinamide, which does not engage the GPR109A receptor responsible for niacin's lipid-modulating effects.
Clinical trials
Randomized comparison of wax-matrix extended-release niacin and IHN in adults with metabolic syndrome
Adults with metabolic syndrome and dyslipidemia
Wax-matrix extended-release niacin produced expected lipid changes, whereas inositol hexanicotinate failed to meaningfully alter lipid parameters compared with baseline. The trial concluded that IHN should not be considered equivalent to pharmaceutical niacin for lipid management.
Double-blind, randomized, placebo-controlled trial of inositol hexanicotinate
Patients with primary Raynaud's phenomenon
The trial reported some symptomatic improvement with IHN compared with placebo in Raynaud's symptoms, although follow-up evidence has been limited and the magnitude of effect modest, leaving the role of IHN uncertain even for peripheral vascular comfort.